论文部分内容阅读
目的研究非小细胞肺癌(NSCLC)原发灶和转移淋巴结中多药耐药蛋白(MDR-1)、核糖核苷酸还原酶M1(RRM-1)、表皮生长因子受体(EGFR)、错配切除修复蛋白1(ERCC-1)表达的差异,并分析这些表达差异性与临床病理类型的关系。方法采用免疫组织化学染色观察46例NSCLC原发灶及转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1蛋白的表达情况,用Wilcoxon秩和检验来比较原发灶和淋巴结转移灶表达是否存在差异,用Fisher检验分析差异性是否与病理类型相关。结果 46例各种病理类型的NSCLC,原发病灶与转移淋巴结均存在MDR-1、RRM-1、EGFR、ERCC-1表达,其中ECRR-1的表达差异在腺癌中具有统计学意义(P=0.026),而MDR-1,RRM-1,EGFR的差异性在各病理类型无统计学意义(P>0.05)。结论 MDR-1、RRM-1、EGFR、ERCC-1在NSCLC的原发病灶和转移淋巴结中均表达,但只有ERCC-1在肺腺癌原发灶与转移淋巴结的表达具有明显差异。
Objective To study the expression of multidrug resistance protein (MDR-1), ribonucleotide reductase M1 (RRM-1) and epidermal growth factor receptor (EGFR) in primary and metastatic lymph nodes of non-small cell lung cancer With the expression of excision repair protein 1 (ERCC-1), and to analyze the relationship between these differences and clinicopathological types. Methods The expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary NSCLC and metastatic lymph nodes were observed by immunohistochemical staining. The Wilcoxon rank sum test was used to compare the expression of MDR-1, Whether there is difference, using Fisher’s test to analyze whether the difference is related to the pathological type. Results The expression of MDR-1, RRM-1, EGFR and ERCC-1 were all found in 46 NSCLC patients with various pathological types and in primary and metastatic lymph nodes. The difference of ECRR-1 expression was statistically significant in adenocarcinoma (P = 0.026). The differences of MDR-1, RRM-1 and EGFR were not statistically significant in all pathological types (P> 0.05). Conclusions MDR-1, RRM-1, EGFR and ERCC-1 are both expressed in primary and metastatic lymph nodes of NSCLC, but only the expression of ERCC-1 in primary lung cancer and metastatic lymph nodes is significantly different.